Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes.
Nucleai has raised $14.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2024.
Nucleai's investors include S32, Vertex Ventures Israel, Fosun RZ Capital, Grove Ventures, M Ventures.
Nucleai is headquartered in Chicago, United States.
Nucleai is a spatial biology company that has developed an AI-powered platform to enhance drug development and improve patient outcomes.
Nucleai is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nucleai — Funding & Investors." VCBacked, April 3, 2024, https://www.vcbacked.co/company/nucleai. Accessed July 20, 2026.
VCBacked. (2024). Nucleai — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/nucleai
{{cite web |title=Nucleai — Funding & Investors |url=https://www.vcbacked.co/company/nucleai |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated